BRPI0511187A - método para tratar cáncer em um indivìduo - Google Patents

método para tratar cáncer em um indivìduo

Info

Publication number
BRPI0511187A
BRPI0511187A BRPI0511187-0A BRPI0511187A BRPI0511187A BR PI0511187 A BRPI0511187 A BR PI0511187A BR PI0511187 A BRPI0511187 A BR PI0511187A BR PI0511187 A BRPI0511187 A BR PI0511187A
Authority
BR
Brazil
Prior art keywords
individual
monoclonal
monoclonal antibodies
antibodies
treatment
Prior art date
Application number
BRPI0511187-0A
Other languages
English (en)
Inventor
Wayne R Kindsvogel
Steven D Hughes
Richard D Holly
Christopher H Clegg
Donald C Foster
Rebecca A Johnson
Mark D Heipel
Pallavur V Sivakumar
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of BRPI0511187A publication Critical patent/BRPI0511187A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MéTODO PARA TRATAR CáNCER EM UM INDIVìDUO São descritos métodos para tratar câncer pela co-administração de um anticorpo monoclonal terapêutico com IL-21. Anticorpos monoclonais exemplares que podem ser usados são rituximab, trastuzumab e anticorpos anti-CTLA-4. O antitumor intensificado da terapia combinada é particularmente útil para populações de pacientes que são recalcitrantes à terapia monoclonal, reincidem após o tratamento com anticorpos monoclonais ou onde o efeito de antitumor de IL-21 intensificado reduz toxicidades associadas com o tratamento usando os anticorpos monoclonais.
BRPI0511187-0A 2004-05-20 2005-05-20 método para tratar cáncer em um indivìduo BRPI0511187A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57297304P 2004-05-20 2004-05-20
US63538004P 2004-12-10 2004-12-10
US67128105P 2005-04-14 2005-04-14
US68044705P 2005-05-12 2005-05-12
PCT/US2005/019126 WO2005113001A1 (en) 2004-05-20 2005-05-20 Methods of treating cancer using il-21 and monoclonal antibody therapy

Publications (1)

Publication Number Publication Date
BRPI0511187A true BRPI0511187A (pt) 2007-12-04

Family

ID=34971701

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511187-0A BRPI0511187A (pt) 2004-05-20 2005-05-20 método para tratar cáncer em um indivìduo

Country Status (16)

Country Link
US (8) US20050265966A1 (pt)
EP (4) EP2425847A1 (pt)
JP (2) JP4982373B2 (pt)
KR (1) KR101236177B1 (pt)
CN (2) CN103127502A (pt)
AU (1) AU2005245031B2 (pt)
BR (1) BRPI0511187A (pt)
CA (1) CA2566745A1 (pt)
CY (1) CY1113287T1 (pt)
DK (1) DK1758610T3 (pt)
ES (1) ES2390278T3 (pt)
HK (1) HK1160776A1 (pt)
IL (1) IL179099A (pt)
PL (1) PL1758610T3 (pt)
PT (1) PT1758610E (pt)
WO (1) WO2005113001A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
PL1758610T3 (pl) * 2004-05-20 2012-11-30 Zymogenetics Inc Sposoby leczenia raka z zastosowaniem IL-21 i terapii przeciwciałem monoklonalnym
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
CA2666426A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
KR100902340B1 (ko) * 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
US8506933B2 (en) * 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
WO2011019670A1 (en) * 2009-08-10 2011-02-17 Nayak Ramesh C Methods of detecting responses to therapies using perforin levels
CA2781664A1 (en) * 2009-11-27 2011-06-03 Msdx, Inc. Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition
US8673309B2 (en) 2011-02-11 2014-03-18 Msdx, Inc. Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1
US9447160B2 (en) * 2012-01-19 2016-09-20 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
SI3128997T1 (sl) 2014-04-08 2020-11-30 Boston Pharmaceuticals Inc. Vezavne molekule specifične za IL-21 in njihove uporabe
KR20160120157A (ko) * 2015-04-07 2016-10-17 주식회사 메드팩토 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
WO2018067602A1 (en) * 2016-10-03 2018-04-12 Baylor College Of Medicine Modulating cytotoxic cell lytic granule positioning to promote diffuse killing in cellular therapies
AU2018333062B2 (en) * 2017-09-15 2022-03-17 Beckman Coulter, Inc. Flow based assays for therapeutics
KR102265437B1 (ko) 2017-11-24 2021-06-15 의료법인 성광의료재단 Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE721983T1 (de) 1988-01-22 2002-07-04 Zymogenetics, Inc. Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
EP2990054A1 (en) * 1998-08-11 2016-03-02 Biogen Inc. Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
ATE330967T1 (de) * 1999-07-02 2006-07-15 Genentech Inc An her2 bindende peptidverbindungen
IT1311703B1 (it) 1999-07-23 2002-03-19 Sipa Spa Impianto ad alta efficienza di soffiaggio di preforme
US6777539B2 (en) 2000-04-05 2004-08-17 Zymogenetics, Inc. Soluble zalpha11 cytokine receptors
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
EP1463524A4 (en) 2001-12-07 2005-02-09 Chiron Corp THERAPEUTIC METHODS FOR TREATING NON-HODGKINIAN LYMPHOMA
AU2003208415B2 (en) * 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
BR0309254A (pt) * 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
EP2377549A1 (en) * 2002-06-07 2011-10-19 ZymoGenetics, Inc. Use of IL-21 for treating viral infections
JP4790413B2 (ja) * 2002-10-08 2011-10-12 イミューノメディクス、インコーポレイテッド 抗体療法
US20070092485A1 (en) * 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
DE60330044D1 (de) * 2002-12-13 2009-12-24 Zymogenetics Inc Il-21-produktion in prokaryontischen wirten
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
MXPA06004199A (es) * 2003-10-17 2006-06-28 Novo Nordisk As Terapia en combinacion.
PL1758610T3 (pl) * 2004-05-20 2012-11-30 Zymogenetics Inc Sposoby leczenia raka z zastosowaniem IL-21 i terapii przeciwciałem monoklonalnym
EP1814580B1 (en) * 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens

Also Published As

Publication number Publication date
IL179099A0 (en) 2007-03-08
EP2431050A8 (en) 2012-09-26
CA2566745A1 (en) 2005-12-01
CY1113287T1 (el) 2016-04-13
JP4982373B2 (ja) 2012-07-25
EP2428216A3 (en) 2012-05-23
US20110086004A1 (en) 2011-04-14
JP2012102122A (ja) 2012-05-31
HK1160776A1 (en) 2012-08-17
AU2005245031A1 (en) 2005-12-01
EP1758610A1 (en) 2007-03-07
US20070178063A1 (en) 2007-08-02
WO2005113001A1 (en) 2005-12-01
ES2390278T3 (es) 2012-11-08
CN103127502A (zh) 2013-06-05
PT1758610E (pt) 2012-10-01
EP2428216A9 (en) 2012-04-25
US20090087404A1 (en) 2009-04-02
DK1758610T3 (da) 2012-10-15
US20110300098A1 (en) 2011-12-08
US20070048264A1 (en) 2007-03-01
EP1758610B1 (en) 2012-07-04
CN102188704B (zh) 2013-04-24
AU2005245031B2 (en) 2011-08-18
EP2428216A2 (en) 2012-03-14
EP2431050A1 (en) 2012-03-21
EP2425847A1 (en) 2012-03-07
JP2007538108A (ja) 2007-12-27
US20070122382A1 (en) 2007-05-31
KR20070026588A (ko) 2007-03-08
KR101236177B1 (ko) 2013-02-22
PL1758610T3 (pl) 2012-11-30
US20050265966A1 (en) 2005-12-01
IL179099A (en) 2011-03-31
US20090269304A1 (en) 2009-10-29
CN102188704A (zh) 2011-09-21

Similar Documents

Publication Publication Date Title
BRPI0511187A (pt) método para tratar cáncer em um indivìduo
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
UA94899C2 (ru) Фиксированное дозирование антител к her
UA89350C2 (uk) Гуманізоване антитіло, що зв'язує людський cd20
BRPI0412890B8 (pt) método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
IL164287A (en) @Human antibodies @ against @@ - ctla @ for use @ in treatment @ cancer
BRPI0611984A2 (pt) uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
NZ601580A (en) Therapeutic methods using anti-cd200 antibodies
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
NO20051345L (no) Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer
MXPA05004919A (es) Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
BR112022026236A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr
WO2020186132A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112019011350A2 (pt) terapia de combinação
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
MX2023002805A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos.
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
BR102012006063A8 (pt) Inibidor de met para uso no tratamento de um paciente sofrendo de um tumor, e, sequência de nucleotídeo
ZA202309150B (en) Antibody against nkp46 and application of antibody
WO2008070090A3 (en) Compositions and methods for diagnosing and treating cancer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.